The current results are consistent with previous studies showing dysregulation of eukaryotic protease inhibitors, such as elafin, in the duodenum of CeD patients54, and the improvement of gluten sensitivity in mouse models after using bacteria producing specific protease inhibitors55. This evidence concerns the gene PI3 and cranioectodermal dysplasia.